The Curious Case Of Gleevec Pricing

Several years ago, a group of oncologists penned an editorial on drug prices, with Gleevec (imatinib mesylate), the  groundbreaking tyrosine kinase inhibitor, as their illustration of egregious pricing practices. This sparked a nationwide conversation on cancer drug prices and value.